Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...

The pulmonary arterial hypertension (PAH) drug preserved its safety profile at 2.5 years of treatment and continued to reduce ...

There have been important recent advances in the management of Crohn's disease, including new classes of biological or small molecule therapies, an appreciation that endoscopic mucosal healing results ...

“Our findings suggest that targeted vitamin D supplementation may be a promising strategy to counter a biological aging ...

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

A recent post-hoc analysis of the SURMOUNT-OSA trials revealed that tirzepatide significantly improves obstructive sleep ...

Many patients with GI conditions turn to complementary and alternative medicine to relieve symptoms or seek a cure. Experts ...

Patients with persistent fish allergy and parvalbumin sensitization had a low threshold for reactions, which were severe, ...

Aficamten was associated with improved peak oxygen uptake and a tolerable safety profile vs. metoprolol, a beta-blocker, in ...

Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...

Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be involved in different ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...